Urotensin II, mouse

Urotensin II, mouse, is a cyclic peptide belonging to the urotensin family, recognized for its role as a potent vasoactive neuropeptide in vertebrates. Structurally characterized by a conserved cyclic hexapeptide core, it exerts its biological effects through the urotensin II receptor (UT receptor), a G protein-coupled receptor widely distributed in cardiovascular, renal, and central nervous systems. The mouse variant of urotensin II is particularly valuable in translational research, as it enables the investigation of species-specific signaling pathways and physiological responses. Its relevance extends to fundamental studies in peptide biology, cardiovascular regulation, and neurohumoral modulation, making it a critical tool for elucidating peptide-receptor interactions and downstream signaling mechanisms in murine models.

Peptide receptor characterization: Urotensin II is frequently employed in receptor binding assays and functional studies aimed at characterizing the UT receptor in murine tissues and cell lines. By applying this peptide in radioligand binding or fluorescence-based assays, researchers can delineate receptor affinity, density, and distribution profiles. Such studies are instrumental in mapping receptor expression patterns and understanding the physiological significance of urotensinergic signaling in mouse models, which serves as a foundation for comparative analyses across species.

Signal transduction research: The compound is widely used to probe intracellular signaling cascades initiated by peptide-receptor engagement. Upon binding to its cognate receptor, urotensin II triggers a cascade of events involving G protein-mediated pathways, such as phospholipase C activation, intracellular calcium mobilization, and downstream kinase signaling. Utilizing this peptide in controlled in vitro systems enables precise dissection of these molecular events, facilitating the identification of critical signaling nodes and potential modulatory factors that influence peptide-induced cellular responses.

Cardiovascular physiology studies: Urotensin II serves as a functional tool for investigating its vasoactive properties in murine cardiovascular systems. Researchers utilize it in isolated vessel preparations, perfused heart models, and in vivo experiments to assess its effects on vascular tone, contractility, and blood pressure regulation. These applications provide key insights into the mechanisms underlying vascular reactivity, endothelial function, and the modulation of hemodynamic parameters in mouse models, contributing to a deeper understanding of cardiovascular homeostasis.

Neuropharmacology and central nervous system research: The peptide is also employed in studies exploring its neuromodulatory roles within the mouse brain and spinal cord. By administering urotensin II to neuronal cultures or brain slices, investigators can assess its influence on neurotransmitter release, synaptic plasticity, and neuronal excitability. Such research elucidates the contribution of urotensinergic signaling to central nervous system function, including behavioral modulation, stress responses, and neuroendocrine regulation in murine systems.

Peptide structure-activity relationship (SAR) analysis: Urotensin II, mouse, is a reference standard in SAR studies aiming to identify the structural determinants of receptor activation and biological efficacy. By comparing the activity of native peptide with synthetic analogs or mutated variants, researchers can pinpoint key amino acid residues and conformational features responsible for receptor binding and downstream effects. These investigations inform the rational design of novel peptide-based probes or modulators, advancing the field of peptide therapeutics discovery and receptor pharmacology.

1. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

2. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

3. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review